PriceTargets.com logo

NASDAQ:AVRO - AVROBIO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 792.86 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$0.84 As of 05/23/2022 05:00 PM ET
▲ +0.05 (6.33%)

This chart shows the closing price for AVRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AVROBIO Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVRO

Analyst Price Target is $7.50
▲ +792.86% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for AVROBIO in the last 3 months. The average price target is $7.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 792.86% upside from the last price of $0.84.

This chart shows the closing price for AVRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in AVROBIO. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/28/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/22/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/23/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2022WedbushLower Price Target$14.00 ➝ $4.00High
5/11/2022BarclaysLower Price Target$6.00 ➝ $4.00High
1/6/2022MizuhoLower Price TargetBuy ➝ Buy$28.00 ➝ $6.00High
1/5/2022Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $3.00High
1/5/2022Wells Fargo & CompanyLower Price TargetOverweight ➝ Overweight$36.00 ➝ $8.00High
1/5/2022Needham & Company LLCLower Price TargetBuy$28.00 ➝ $8.00High
1/5/2022BTIG ResearchDowngradeBuy ➝ NeutralHigh
1/5/2022BarclaysBoost Price TargetOverweight ➝ Overweight$6.00 ➝ $22.00High
1/4/2022Stifel EuropeLower Price Target$9.00 ➝ $4.00High
11/19/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$24.00 ➝ $7.00High
10/12/2021Morgan StanleyLower Price TargetOverweight$27.00 ➝ $25.00High
8/6/2021BTIG ResearchReiterated RatingBuy$23.00High
7/16/2021Morgan StanleyLower Price TargetOverweight$31.00 ➝ $29.00High
6/14/2021BTIG ResearchInitiated CoverageBuy$23.00High
5/27/2021Needham & Company LLCInitiated CoverageBuy$28.00High
5/14/2021Morgan StanleyLower Price TargetOverweight$34.00 ➝ $31.00High
5/14/2021MizuhoReiterated RatingBuy$28.00High
5/4/2021Wells Fargo & CompanyLower Price TargetOverweight$58.00 ➝ $36.00High
5/4/2021MizuhoLower Price TargetBuy$43.00 ➝ $28.00High
5/3/2021SVB LeerinkLower Price TargetMarket Perform$18.00 ➝ $10.00High
3/21/2021SVB LeerinkReiterated RatingHold$18.00Medium
3/9/2021BarclaysInitiated CoverageOverweight$23.00High
3/1/2021Stifel NicolausInitiated CoverageHold$14.00Low
11/18/2020MizuhoBoost Price TargetPositive ➝ Buy$35.00 ➝ $43.00High
11/11/2020Berenberg BankInitiated CoverageBuy$27.00High
11/5/2020SVB LeerinkReiterated RatingMarket PerformHigh
10/13/2020Morgan StanleyLower Price TargetOverweight$35.00 ➝ $34.00Low
10/6/2020WedbushReiterated RatingOutperform$36.00High
9/15/2020MizuhoReiterated RatingBuy$35.00High
8/7/2020WedbushReiterated RatingPositive ➝ Outperform$36.00Medium
7/15/2020Morgan StanleyLower Price TargetOverweight$37.00 ➝ $35.00Medium
5/14/2020HC WainwrightReiterated RatingHold$13.00High
5/8/2020MizuhoReiterated RatingBuy$35.00Low
4/1/2020MizuhoReiterated RatingBuyHigh
3/31/2020Morgan StanleyLower Price TargetOverweight$40.00 ➝ $37.00High
3/31/2020HC WainwrightDowngradeBuy ➝ Neutral$35.00 ➝ $13.00High
3/16/2020CowenReiterated RatingBuyHigh
2/19/2020Nomura SecuritiesBoost Price Target$35.00 ➝ $40.00Low
2/12/2020Morgan StanleyBoost Price TargetOverweight$37.00 ➝ $40.00High
2/11/2020HC WainwrightReiterated RatingBuy$35.00Medium
2/11/2020MizuhoBoost Price TargetBuy$28.00 ➝ $35.00Medium
2/5/2020HC WainwrightReiterated RatingBuy$35.00High
11/8/2019Janney Montgomery ScottReiterated RatingBuyHigh
11/8/2019HC WainwrightReiterated RatingBuy$35.00High
10/28/2019Nomura SecuritiesInitiated CoverageBuy$35.00Low
8/11/2019MizuhoReiterated RatingBuy$28.00High
8/9/2019WedbushReiterated RatingOutperform$43.00High
8/9/2019HC WainwrightReiterated RatingBuy$35.00High
7/15/2019CowenReiterated RatingBuyLow
6/26/2019MizuhoInitiated CoverageBuy ➝ Buy$28.00High
5/14/2019HC WainwrightSet Price TargetBuy$40.00Low
5/14/2019CowenReiterated RatingBuyHigh
5/2/2019CowenReiterated RatingBuyHigh
4/22/2019HC WainwrightSet Price TargetBuy$40.00Low
4/5/2019Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$34.00 ➝ $24.42High
3/26/2019HC WainwrightSet Price TargetBuy$40.00High
1/17/2019SVB LeerinkLower Price TargetPositive ➝ Market Perform$27.00 ➝ $19.00High
1/15/2019HC WainwrightReiterated RatingBuyMedium
11/27/2018SVB LeerinkInitiated CoverageMarket PerformHigh
10/9/2018GuggenheimInitiated CoverageBuy ➝ BuyMedium
10/2/2018HC WainwrightReiterated RatingBuy ➝ Buy$47.00 ➝ $40.00High
9/17/2018HC WainwrightInitiated CoverageBuy ➝ BuyHigh
8/13/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$37.00 ➝ $40.00Low
7/16/2018Wells Fargo & CompanyInitiated CoverageOutperform$40.00High
7/16/2018CowenInitiated CoverageOutperformHigh
7/16/2018Morgan StanleyInitiated CoverageOverweight$37.00High
7/16/2018WedbushInitiated CoverageOutperform$38.00High
(Data available from 5/24/2017 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2021
  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2021
  • 4 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2022
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2022
  • 9 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2022

Current Sentiment

  • 9 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

AVROBIO logo
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $0.84
Low: $0.75
High: $1.00

50 Day Range

MA: $1.13
Low: $0.75
High: $1.62

52 Week Range

Now: $0.84
Low: $0.74
High: $11.00

Volume

447,248 shs

Average Volume

691,825 shs

Market Capitalization

$36.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

Frequently Asked Questions

What sell-side analysts currently cover shares of AVROBIO?

The following equities research analysts have issued stock ratings on AVROBIO in the last twelve months: Barclays PLC, BTIG Research, Mizuho, Morgan Stanley, Needham & Company LLC, Stifel Europe, Wedbush, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for AVRO.

What is the current price target for AVROBIO?

0 Wall Street analysts have set twelve-month price targets for AVROBIO in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 792.9%.
View the latest price targets for AVRO.

What is the current consensus analyst rating for AVROBIO?

AVROBIO currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AVRO will outperform the market and that investors should add to their positions of AVROBIO.
View the latest ratings for AVRO.

How do I contact AVROBIO's investor relations team?

AVROBIO's physical mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 914-8420 and its investor relations email address is [email protected] The official website for AVROBIO is www.avrobio.com. Learn More about contacing AVROBIO investor relations.